Israel is on the edge of unveiling another ground-breaking treatment for mental conditions. This latest approach aims to resolve specific mental ailments using small doses of psilocybin.
Madrigal Mental Care is an Israeli biopharmaceutical company, and it is behind this novel modern medical treatment. The company announced that it would unveil the developed nanotechnology this week at the Biomed Israel 2022 event. According to the press release, the treatment uses a nasal spray to prevent and manage post-traumatic stress disorder (PTSD) symptoms. The pharmaceutical event was held in Tel Aviv, Israel, at the David Intercontinental Hotel.
The Biomed Israel event is held as a tribute to celebrate the technology and life sciences industry. At least 5,000 people have attended the past events organized by this body. Out of this lot, over 1,000 attendees are international participants from over 40 countries
The latest treatment
Israel’s Madrigal Mental Care revealed that the nasal spray system is an effective nose-to-brain delivery system. With this technique, the user will receive the encapsulated molecule of psilocybin (psychedelic substance), and it will be absorbed into the bloodstream almost immediately.
Professor Amnon Sintov of the Department of Biomedical Engineering at Ben-Gurion University of the Negev (BGU) made this incredible nanotechnology invention. The spray can administer other drugs like MDMA, Ketamine, mescaline, and other psychedelics. Sintov operates under the BGU technology licensing (that is, BGU’s technology transfer company).
Professor Amnon Sintov said that many studies had investigated the benefits of using psychedelic drugs to treat mental disorders like depression, anxiety, addiction, obsessive-compulsive disorder (OCD), and PTSD. He says most of these studies have shown proof that psychedelics are effective.
Psychedelics have an intense effect on the human brain. Sintov pointed out that safe and precise dose delivery of psychedelics is the only way to exploit their therapeutic benefits.
Sintov explained that his brilliant innovation would ensure precise drug doses are wholly encapsulated in nanoparticles. These tiny particles are then sent to the brain through an intranasal spray. He added that the technique is fast, safe, and efficient.
Research on psilocybin continues
Recently, more researchers are basing their studies on the effectiveness of psilocybin in resolving depression and PTSD symptoms. They’re also looking into the use of psychedelics for end-of-life care.
Psilocybin is a proven 5-HT2A agonist. This suggests that the drug would render multiple therapeutic effects in several areas. Also, note that the brain’s cortex has numerous 5-HT2A receptors that affect creativity, reflection, and thinking.
Madrigal Mental Care Co-founder and Chairman David Gabay said that the novel technology would quickly deliver the prescribed doses of psychoactive substances. He stressed that the nanoparticles are biodegradable. Compared to other treatments, this provides better stability to the client and higher chances of delivering accurate results.
Another in vitro study, which was completed at BGU’s Department of Biochemistry and Pharmacology, observed that inflamed brain cell cultures show an improvement are administered as nanoparticles. One of the researchers on ground, Professor Shimon Ben-Shabat, said that the team would be starting preclinical trials in weeks. He explained that the proposed study would be carried out with rodents. At the end of the study, the researchers hope for safety and efficacy approvals to kickstart clinical trials by next year.
According to Ben-Shabat and other scientists on board the investigative study, this newest nanotechnology technique of administering psychedelics can push the entire field of psychedelic-based treatments forward. The success of this treatment program in the preclinicals and clinicals would be to the benefit of thousands, if not millions, of people worldwide suffering from acute or chronic mental conditions, most specifically depression and Post Traumatic Stress Disorder (PTSD).
A growing need for alternative therapies
The medical sector is about to get to a crossroads where patients have grown tolerant of the available conventional drugs being administered. The industry has gotten to a stage where it needs multiple treatment options, including non-conventional strategies.
The increasing research into psilocybin and cannabis puts the sector on the right track. When conventional therapies fail, medical practitioners would be able to fall on alternative therapies like the use of cannabis or psilocybin-derived drugs. The drugs would be produced so that the users would be able to use them and see results as soon as possible.
The Senior Vice President of Business Development, BioPharma, Dr. Galit Mazoon Perlmutter, mentioned that the medical industry has a dire need for better treatments to help people suffering from PTSD and other mental disorders. Perlmutter disclosed that BGU Technologies applied to submit the nanotechnology intranasal spray as their patent. Their discovery could be one of the most important breakthroughs in alternative medical treatments this decade. No one can deny that top scientists at Ben-Gurion University are putting in the work.
Funny enough, this subject used to be a regular topic of discourse on inline forums like Reddit. Today, the world is keen on knowing the advantages microsoding psilocybin could induce. Patients suffering from PTSD, depression, and other mental disorders can now look forward to a breakthrough treatment.
In the United States, the FDA recently approved an esketamine nasal spray. Available reports claim that this nasal sprays would be used in different clinics in all legal regions of the country. Some months ago, A New York Psychiatrist observed that shrooms significantly reduced the levels of distress suffered by cancer patients. The New York University says it now has a learning module further to investigate the therapeutic benefits and side effects of shrooms.
Back in Isreal, the country has always been an avid supporter of cannabis treatments. In fact, Israel is home to a host of cannabis-related medical device development. The country’s support for advanced research on cannabis and psychedelics gives the commoner hope that these alternative treatments will soon be available.
Israel’s health sector is one of the best globally, and the government continues to provide enough funds to run experiments for the health sector to thrive. Biomed Conference organizers have disclosed that they’re preparing for much larger participation in the next event. They also said they’d extend the invites to members of other sectors. According to The Times of Israel, the next event would focus on cancer treatment and organic food. Who knows what novel discovery would be unveiled by then.